Home » Topics » Regulatory » EMA

EMA
RSS

MultiStem receives orphan drug designation in Europe

Dec. 18, 2013

EMA accepts Fibrocaps MAA for review

Nov. 29, 2013

EMA grants accelerated assessment to faldaprevir

Nov. 27, 2013

Celgene receives positive CHMP opinion for Abraxane in combination with gemcitabine

Nov. 26, 2013

Ariad Pharmaceuticals obtains positive CHMP opinion on the continued use of Iclusig

Nov. 26, 2013

Dimethyl fumarate in Tecfidera qualifies as new active substance in Europe

Nov. 25, 2013

Deltyba obtains European CHMP recommendation upon re-examination

Nov. 25, 2013

Positive CHMP opinion for cetuximab in RAS wild-type metastatic colorectal cancer

Nov. 25, 2013

EMA's CHMP supports approval of Xigduo for type 2 diabetes

Nov. 25, 2013

European CHMP recommends approval of Sovaldi

Nov. 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...